Effects of myocardial transplantation of mesenchymal stem cells transfected with vascular endothelial factor gene on improvement of heart function and angiogenesis after myocardial infarction: Experiment with rats

National Medical Journal of China

Volumn 86, Issue 15, 2006, Pages 1027-1034

  Yang, Jin Fu ^a   Zhou, Wen Wu ^b   Tang, Tao ^b   Yu, Jie Feng ^b   Zhou, Xin Min ^b   Hu, Jian Guo ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NONE

Author keywords

Gene therapy; Heart infarction; Stem cell; Vascular endothelial growth factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BROXURIDINE; COMPLEMENTARY DNA; EVANS BLUE; LIPOSOME; MESSENGER RNA; PLASMID DNA; TROPONIN T; VASCULOTROPIN 165;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL CULTURE; CELL ISOLATION; CELL SURVIVAL; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENETIC TRANSFECTION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE PERFUSION; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPARATION TECHNIQUE; STEM CELL GENE THERAPY; TREATMENT OUTCOME; VISUAL FIELD; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; GENE THERAPY; HEART; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RANDOM ALLOCATION; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745467494     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Reinhardt D, Sigusch HH, Hensse J, et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart, 2002, 88: 525-530.
2. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med, 2001, 344: 1750-1757.
3. Miller P, Pfeiffer P, Koglin J, et al. Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation, 2002, 106: 31-35.
4. Herlitz J, Dellborg M, Karlson BW, et al. Prognosis after acute myocardial infarction continues to improve in the reperfusion era in the community of Goteborg. Am Heart J, 2002, 144: 89-94.
5. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet, 1987, 20: 263-272.
6. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart Circulation, 2002, 105: 93-98.
7. Mosca JD, Hendricks JK, Buyaner D, et al. Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res, 2000, S71-90.
8. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med, 2003, 9: 1195-1201.
9. Chinese source. 2004, 4: 226-230.
10. Chinese source. 2004, 4: 562-564.
11. Coles LS, Diamond P, Lambrusco, et al. A novel mechanism of repression of the vascular endothelial growth factor promoter, by single strand DNA binding cold shock domain (Y-box) proteins in normoxic fibroblasts. Nucleic Acids Research, 2002, 30: 4845-4854.
12. Fraser JK, Schreiber RE, Zuk PA, et al. Adult stem cell therapy for the heart. Int J Biochem Cell Biol, 2004, 36: 658-666.
13. Sam J, Angoulvant D, Fazel S, et al. Heart cell implantation after myocardial infarction. Coron Artery Dis, 2005, 16: 85-91.
14. Medvinsky A, Smith A. Stem cells: fusion brings down barriers. Nature, 2003, 422: 823-825.
15. Zhang S, Wang D, Estro Z, et al. Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation, 2004, 110: 3803-3807.
16. Chinese source. 2005, 85:3342-3345.
17. Chachques JC, Acar C, Herreros J, et al. Cellular cardiomyoplasty: clinical application. Ann Thorac Surg, 2004, 77: 1121-1130.
18. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res, 2000, 46: 214-224.
19. Fedak PW, Altamentova SM, Weisel RD, et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol, 2003, 284: H626-H634.
20. Jain M, Pfister O, Hajjar RJ, et al. Mesenchymal stem cells in the infarcted heart. Coron Artery Dis, 2005, 16: 93-97.
21. Pedrottya DM, Niklason LE. Angiogenesis therapies for cardiovascular disease. Current Opinion in Anaesthesiology, 2003, 16: 3-9.
22. Coles LS, Diamond P, Lambrusco L, et al. A novel mechanism of repression of the vascular endothelial growth factor promoter, by single strand DNA binding cold shock domain (Y-box) proteins in normoxic broblasts. Nucleic Acids Res, 2002, 30: 4845-4854.
23. Ozawa CR, Banfi A, Glazer NL, et al. Microenviromental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest, 2004, 113: 516-527.
24. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med, 2000, 6: 389-395.